"The encouraging effect of AQX-1125 observed on the primary endpoint of reduction in pain together with several statistically significant secondary endpoints, underscore the potential of AQX-1125 as a once daily, oral therapy for this debilitating disease," said CEO David Main in a press release.
AQX-1125 is being developed for other indications as well. A phase II study in atopic dermatitis is currently ongoing with results expected in the fourth quarter, earlier than previously forecasted (end of the first quarter of 2016). Meanwhile, as far as evaluating the candidate for chronic obstructive pulmonary disease (COPD) exacerbations is concerned, the company has decided not to go ahead with the development of the candidate for this indication given disappointing top-line data from a phase II study (FLAGSHIP).
The Target Market
Aquinox Pharmaceuticals Inc. Watchlist
NASDAQ3:59 PM EDT
Johnson & Johnson Cashes Out Of Aquinox Pharmaceuticals' Parabolic Rally Benzinga 2 hrs 43 mins ago
Trapped Buyers Attempt To Flee Aquinox Pharmaceuticals Benzinga 1 day 0 hrs ago
BPS/IC, a chronic inflammatory bladder disease, is estimated to affect about 5 - 12 million people in the U.S. Most BPS/IC patients continue to suffer from this debilitating condition despite treatment with existing therapies. Most current therapies as well as those being developed are focused mainly on symptomatic relief of BPS/IC. Aquinox reported that no new oral treatments for BPS/IC have been approved by the FDA in the last 20 years.
he does this all the time. he just fabricates things. he never shorted it at $45. He just tries to pretend in his mind.
He bragged about shorting at $13 before it ran up to $50.. Look at his history. It's real bad. he said load up on OHRP because Bakers brothers buying but he liked and that stock has fallen from $4 to $2.
How are they able to know that Johnson and Johnson sold? Note in insider trading that Johnson and Johson was selling at $7 back in October 2014. also.
what a pump and dump
Yup, yup yup
Do you know how stupid this guy is?
I can’t imagine that the Citigroup analyst just on a hunch reiterated a Buy with higher price target. It is more likely that he knows something very positive is to be released and thus was willing to stick his neck out in the teeth of the forthcoming 10Q. He can’t be stupid enough to do this and damage his reputation. He could simply have done what most analysts do, as he has done in the past: wait until the numbers and data is out, reevaluate and update rating. Why in front of the data? On balance, I think the news will be good and the stock can be up by 50 – 60 percent.
Valuation is under $200 million. If this is accurate and the past Phase 3, this should be at least in $500 million.
Down -8% after up 40%?
Then why have so many insiders bought at higher prices in the $60-70?